Jazz Pharmaceuticals plc

NASDAQ:JAZZ   3:32:29 PM EDT
120.94
+0.43 (+0.36%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)7.54B
Current PE18.18
Forward PE 6.38
2yr Forward PE 5.74
See more stats
Estimates Current Quarter
Revenue$956.83 Million
Adjusted EPS$4.20
See more estimates
10-Day MA$120.95
50-Day MA$122.48
200-Day MA$126.84
See more pivots

Jazz Pharmaceuticals plc Stock, NASDAQ:JAZZ

Waterloo Exchange, Waterloo Road, Dublin, Dublin 4
Ireland
Phone: +353.1.634.7800
Number of Employees: 2800

Description

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.